Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Geriatric Research, Education and Clinical Center, James J. Peters Veterans Affairs Medical Center, Bronx, New York.
School of Nursing, Oregon Health and Science University, Portland, Oregon.
Clin Ther. 2018 Apr;40(4):512-525. doi: 10.1016/j.clinthera.2018.02.017. Epub 2018 Mar 20.
Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, has a rapidly rising prevalence in the United States and a very poor overall rate of survival. This epidemic is driven by the cohort of aging Baby Boomers with hepatitis C viral infection and the increasing prevalence of cirrhosis as a result of nonalcoholic steatohepatitis. Because curative options are limited, the disease course creates, in patients and their families, distressing uncertainty around prognosis and treatment decisions. Older adults are disproportionately affected by HCC and have more comorbidities, adding to the complexity of the disease. This population would benefit from increased access to palliative care services, which can potentially complement the treatments throughout the disease trajectory. The purpose of this review was to use existing evidence to propose a new model of palliative care integration in patients with HCC. Thus, we focus on the HCC stage and the treatment algorithm, the ways that palliative care can offer support in this population at each stage, as well as elements that can enhance patient and family support throughout the entire disease trajectory, with an emphasis on the care of older adults with HCC.
This is a narrative review in which we identify evidence-based ways that palliative care can help younger and older adults with HCC and their families, at each stage of HCC and throughout the disease trajectory.
We propose ways to integrate HCC and palliative care based on the existing evidence in both fields. Palliative care offers support in symptom management, advanced care planning, and decision making in ways that are specific to each stage of HCC. We also discuss the evidence that illustrates the palliative care needs of patients with HCC that span the entire course of illness, including coping with the stigmatization of liver disease, addressing informational needs at different stages, and discussing quality of life longitudinally.
Integrating palliative care into the treatment of patients with HCC has the potential to improve outcomes, although more research is needed to build this evidence base.
肝细胞癌(HCC)是最常见的原发性肝癌,其在美国的发病率迅速上升,整体生存率非常低。这种流行趋势是由感染丙型肝炎病毒的婴儿潮一代人群老龄化以及非酒精性脂肪性肝炎导致的肝硬化患病率增加所驱动的。由于治疗选择有限,疾病的发展过程给患者及其家属带来了预后和治疗决策方面的巨大不确定性。老年人受到 HCC 的影响不成比例,且合并症更多,这增加了疾病的复杂性。这一人群将受益于更多的姑息治疗服务,姑息治疗可以在整个疾病过程中为治疗提供补充。本综述的目的是利用现有证据提出 HCC 患者姑息治疗整合的新模式。因此,我们重点关注 HCC 分期和治疗算法,姑息治疗在该人群的每个阶段可以提供支持的方式,以及在整个疾病过程中可以增强患者和家属支持的因素,重点关注 HCC 老年患者的护理。
这是一篇叙述性综述,我们确定了姑息治疗可以帮助 HCC 年轻和老年患者及其家属的循证方法,以及在 HCC 的每个阶段和整个疾病过程中。
我们根据这两个领域的现有证据提出了将 HCC 和姑息治疗相结合的方法。姑息治疗在症状管理、预先护理计划和决策制定方面提供支持,具体取决于 HCC 的每个阶段。我们还讨论了说明 HCC 患者姑息治疗需求的证据,这些需求贯穿整个疾病过程,包括应对肝脏疾病的污名化、在不同阶段满足信息需求以及纵向讨论生活质量。
将姑息治疗纳入 HCC 患者的治疗中有可能改善治疗结果,尽管需要更多的研究来建立这一证据基础。